Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- London
- Most recent report
- 8-K, filed Oct 19, 2026
- Filings on record
- 274 filings
- On EDGAR
- CIK 1479615
- Filer status
- Non-accelerated filer, Smaller reporting company
Financials 8 of 79
News 8 of 23
Prospectuses and Registrations 8 of 23
- 424B5 Prospectus supplement for an offering Aug 12, 2026
- 424B5 Prospectus supplement for an offering Aug 10, 2026
- 424B5 Prospectus supplement for an offering May 27, 2026
- S-3 Shelf registration statement May 18, 2026
- S-8 Registration statement for an employee plan Mar 5, 2026
- S-8 Registration statement for an employee plan Feb 27, 2025
- 424B3 Prospectus supplement for an offering May 14, 2024
- F-3 May 7, 2024
Proxies 5
Ownership 8 of 97
- SCHEDULE 13G/A Large holder reported a passive stake, amended Oct 13, 2026
- SCHEDULE 13G Large holder reported a passive stake Oct 13, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Aug 13, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- 4 Insider reported a trade Aug 13, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Jul 8, 2026
- 4 Insider reported a trade Jul 7, 2026
- 4 Insider reported a trade Feb 13, 2026
Other 8 of 47
- S-3MEF Aug 11, 2026
- EFFECT Notice that a registration became effective May 27, 2026
- CORRESP Reply to SEC staff May 22, 2026
- UPLOAD Comment letter from SEC staff May 22, 2026
- ARS Annual report sent to shareholders Apr 29, 2026
- UPLOAD Comment letter from SEC staff Jan 9, 2026
- CORRESP Reply to SEC staff Dec 31, 2025
- UPLOAD Comment letter from SEC staff Dec 18, 2025
Everything here comes from Silence Therapeutics plc's own filings on SEC EDGAR. The filing list is rechecked every hour.